Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Tesamorelin, Stabilized GHRH(1-44) analog
A stabilized synthetic analog of GHRH(1-44) that resists DPP-IV degradation, FDA approved to reduce excess visceral abdominal fat in HIV associated lipodystrophy.

A stabilized GHRH analog that nudges the pituitary to release growth hormone in natural pulses, how it trims visceral fat while keeping the body's feedback loop intact.
HIV lipodystrophy
Liver fat
Pituitary mediated GH
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Falutz J, et al.
In a double blind RCT, tesamorelin produced a highly significant, selective reduction in visceral fat with improved lipids over 26 weeks.
FDA approved for reduction of excess visceral abdominal fat in HIV associated lipodystrophy, on the basis of two double blind, randomized, placebo controlled trials. Effects were modest (waist circumference ~2 cm) and not sustained after discontinuation. Also studied off label (e.g., NAFLD). Egrifta SV approved Oct 2019; weekly Egrifta WR approved 2025.
Arthralgia, injection site reactions, peripheral edema, extremity pain. Raises IGF-1 (long term oncologic risk unknown). Long term cardiovascular safety beyond one year not established.
Pregnancy; active malignancy; disrupted pituitary axis; hypersensitivity.
FDA approved (the only drug for HIV lipodystrophy; Theratechnologies). WADA prohibited (S2, named GHRH analog).
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.